



June 16, 2021

Re: New Prescription Drug Notice From Novo Nordisk Inc. – Wegovy™

Dear Vermont Attorney General Office,

Pursuant to 18 V.S.A. §4637 (b), Novo Nordisk In. is providing notification of a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

<b>NDC</b>	<b>Drug Product Description</b>	<b>Introduced to Market Date</b>	<b>WAC at Intro to Market</b>
00169-4525-14	Wegovy™ 0.25 mg/0.5 mL in 1 pre-filled pen; 4 pens in 1 carton	6/16/2021	\$ 1,349.02
00169-4505-14	Wegovy™ 0.5 mg/0.5 mL in 1 pre-filled pen; 4 pens in 1 carton	6/16/2021	\$ 1,349.02
00169-4501-14	Wegovy™ 1 mg/ 0.5 mL in 1 pre-filled pen; 4 pens in 1 carton	6/16/2021	\$ 1,349.02
00169-4517-14	Wegovy™ 1.7 mg/0.75 mL in 1 pre-filled pen; 4 pens in 1 carton	6/16/2021	\$ 1,349.02
00169-4524-14	Wegovy™ 2.4 mg/0.75 mL in 1 pre-filled pen; 4 pens in 1 carton	6/16/2021	\$ 1,349.02

We will submit to the Department the additional information required under 18 V.S.A. §4637 (b) within 30 days of this initial submission.

Sincerely,

Amie Phillips Pablo  
Director, Ethics & Compliance  
Novo Nordisk Inc.